This study is currently not recruiting participants.

Individual Patient Expanded Access for use of gilteritinib (ASP2215)

Investigation of an Investigational Medication for Acute Myeloid Leukemia with FLT3 Mutation

Not Recruiting
18 years - 100 years
All
Phase N/A

Brief description of study.

This is a request for an individual patient expanded access for use of gilteritinib (ASP2215) for subjects with relapsed/refractory acute myeloid leukemia (AML) with FLT3 mutation.

Detailed description of study

This is a request for an individual patient expanded access for use of gilteritinib (ASP2215) for subjects with relapsed/refractory acute myeloid leukemia (AML) with FLT3 mutation.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: acute myeloid leukemia
  • Age: 18 years - 100 years
  • Gender: All

This study investigates the use of an investigational medication for people with a type of blood cancer called acute myeloid leukemia (AML) that has come back or has not responded to treatment. The study focuses on individuals who have a specific change in their genes known as the FLT3 mutation, which can affect how the cancer grows.

Participants in this study will receive the investigational medication to see how it affects their AML. The study will monitor the participants' response to the medication and any side effects they might experience.

  • Who can participate: Adults with relapsed or refractory acute myeloid leukemia and a confirmed FLT3 mutation may be eligible to participate.
  • Study details: Participants will take the investigational medication as directed by the study team. The effects of the medication on their leukemia will be closely monitored throughout the study.
Updated on 19 Feb 2024. Study ID: 1704132255 (PHO-PRADHAN-A

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team